OBSOLETE: Xeroderma pigmentosum complementation group B

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:276252
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Xeroderma pigmentosum complementation group B (XP-B) is an extremely rare autosomal recessive disorder caused by mutations in the ERCC3 (XPB) gene, which encodes a DNA helicase essential for nucleotide excision repair (NER) and transcription. This Orphanet entry (276252) is marked as OBSOLETE, meaning it has been reclassified or merged into other clinical entities. Mutations in the ERCC3/XPB gene can give rise to a spectrum of overlapping phenotypes, including xeroderma pigmentosum (XP), XP combined with Cockayne syndrome (XP/CS), and trichothiodystrophy (TTD). Because of this phenotypic variability, the complementation group B designation has been reorganized under these broader diagnostic categories rather than maintained as a standalone entity. Classically, patients with XP-B-related disease present with extreme sensitivity to ultraviolet (UV) radiation, leading to severe sunburn reactions, freckling, and a markedly increased risk of skin cancers at a young age. The skin, eyes, and nervous system are the primary body systems affected. Ocular manifestations include photophobia, keratitis, and potential corneal opacification. Progressive neurological degeneration, including sensorineural hearing loss, cognitive decline, and peripheral neuropathy, may occur, particularly in patients with combined XP/CS features. Some patients also exhibit growth failure and characteristic facial features associated with Cockayne syndrome. There is no cure for XP-B-related conditions. Management is centered on rigorous UV protection, including avoidance of sunlight, use of protective clothing, UV-filtering eyewear, and regular dermatologic surveillance for early detection and treatment of skin cancers. Neurological and developmental complications require multidisciplinary supportive care. Patients should be referred to specialized centers experienced in managing DNA repair disorders for optimal long-term follow-up.

Also known as:

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: Xeroderma pigmentosum complementation group B.

View clinical trials →

No actively recruiting trials found for OBSOLETE: Xeroderma pigmentosum complementation group B at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Xeroderma pigmentosum complementation group B community →

No specialists are currently listed for OBSOLETE: Xeroderma pigmentosum complementation group B.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: Xeroderma pigmentosum complementation group B.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Xeroderma pigmentosum complementation group BForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Xeroderma pigmentosum complementation group B.

Start the conversation →

Latest news about OBSOLETE: Xeroderma pigmentosum complementation group B

No recent news articles for OBSOLETE: Xeroderma pigmentosum complementation group B.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about OBSOLETE: Xeroderma pigmentosum complementation group B

What is OBSOLETE: Xeroderma pigmentosum complementation group B?

Xeroderma pigmentosum complementation group B (XP-B) is an extremely rare autosomal recessive disorder caused by mutations in the ERCC3 (XPB) gene, which encodes a DNA helicase essential for nucleotide excision repair (NER) and transcription. This Orphanet entry (276252) is marked as OBSOLETE, meaning it has been reclassified or merged into other clinical entities. Mutations in the ERCC3/XPB gene can give rise to a spectrum of overlapping phenotypes, including xeroderma pigmentosum (XP), XP combined with Cockayne syndrome (XP/CS), and trichothiodystrophy (TTD). Because of this phenotypic varia

How is OBSOLETE: Xeroderma pigmentosum complementation group B inherited?

OBSOLETE: Xeroderma pigmentosum complementation group B follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does OBSOLETE: Xeroderma pigmentosum complementation group B typically begin?

Typical onset of OBSOLETE: Xeroderma pigmentosum complementation group B is childhood. Age of onset can vary across affected individuals.